Clinical Trial: A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625618) titled 'A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function' on May 09.

Brief Summary: This study is a single-center, non-randomized, open-label, parallel, single-dose study to evaluate the PK profile and safety of MY008211A Tablets in subjects with hepatic impairment.

Study Start Date: Sept. 20, 2024

Study Type: INTERVENTIONAL

Condition: Hepatic Insufficiency (MeSH ID: D048550)

Intervention: DRUG: MY008211A tablets

Each subject will take a single oral dose of 400 mg MY008211A Tablets under fasting conditions.

Recruitment Status: COMPLETED

Sponsor: Wuhan Createrna Science and ...